- Home
- BRLT vs CARM Comparison
BRLT vs CARM Comparison
Compare BRLT & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLT
- CARM
- Stock Information
- Founded
- BRLT 2005
- CARM 2016
- Country
- BRLT United States
- CARM United States
- Employees
- BRLT N/A
- CARM N/A
- Industry
- BRLT Consumer Specialties
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- BRLT Consumer Discretionary
- CARM Health Care
- Exchange
- BRLT Nasdaq
- CARM Nasdaq
- Market Cap
- BRLT 22.6M
- CARM 19.7M
- IPO Year
- BRLT 2021
- CARM N/A
- Fundamental
- Price
- BRLT $1.37
- CARM $0.45
- Analyst Decision
- BRLT Hold
- CARM Hold
- Analyst Count
- BRLT 5
- CARM 5
- Target Price
- BRLT $2.40
- CARM $4.57
- AVG Volume (30 Days)
- BRLT 95.6K
- CARM 514.4K
- Earning Date
- BRLT 03-12-2025
- CARM 03-31-2025
- Dividend Yield
- BRLT N/A
- CARM N/A
- EPS Growth
- BRLT N/A
- CARM N/A
- EPS
- BRLT 0.03
- CARM N/A
- Revenue
- BRLT $426,982,000.00
- CARM $20,268,000.00
- Revenue This Year
- BRLT N/A
- CARM $46.34
- Revenue Next Year
- BRLT $1.04
- CARM N/A
- P/E Ratio
- BRLT $49.86
- CARM N/A
- Revenue Growth
- BRLT N/A
- CARM 41.13
- 52 Week Low
- BRLT $1.25
- CARM $0.38
- 52 Week High
- BRLT $3.21
- CARM $2.77
- Technical
- Relative Strength Index (RSI)
- BRLT 31.80
- CARM 44.17
- Support Level
- BRLT $1.25
- CARM $0.43
- Resistance Level
- BRLT $1.75
- CARM $0.50
- Average True Range (ATR)
- BRLT 0.12
- CARM 0.05
- MACD
- BRLT -0.03
- CARM 0.00
- Stochastic Oscillator
- BRLT 21.82
- CARM 28.16
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. Its sales consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.